Aaron I. Davis Sells 100,000 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock

iTeos Therapeutics, Inc. (NASDAQ:ITOSGet Rating) Director Aaron I. Davis sold 100,000 shares of iTeos Therapeutics stock in a transaction on Monday, May 2nd. The stock was sold at an average price of $27.49, for a total value of $2,749,000.00. Following the transaction, the director now directly owns 2,817,058 shares of the company’s stock, valued at approximately $77,440,924.42. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

NASDAQ:ITOS opened at $28.00 on Tuesday. The firm has a market cap of $994.42 million, a P/E ratio of 5.00 and a beta of 1.91. iTeos Therapeutics, Inc. has a 52-week low of $17.43 and a 52-week high of $52.43. The stock’s fifty day moving average price is $33.29.

Separately, Zacks Investment Research downgraded iTeos Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 26th.

A number of institutional investors have recently bought and sold shares of ITOS. Rubric Capital Management LP purchased a new stake in iTeos Therapeutics during the 3rd quarter worth about $26,694,000. Tang Capital Management LLC increased its position in iTeos Therapeutics by 310.2% during the 3rd quarter. Tang Capital Management LLC now owns 900,000 shares of the company’s stock worth $24,300,000 after purchasing an additional 680,604 shares in the last quarter. RTW Investments LP increased its position in iTeos Therapeutics by 37.1% during the 3rd quarter. RTW Investments LP now owns 2,353,015 shares of the company’s stock worth $63,531,000 after purchasing an additional 636,430 shares in the last quarter. Pacer Advisors Inc. purchased a new stake in iTeos Therapeutics during the 1st quarter worth about $14,271,000. Finally, State Street Corp increased its position in iTeos Therapeutics by 137.0% during the 4th quarter. State Street Corp now owns 763,351 shares of the company’s stock worth $35,542,000 after purchasing an additional 441,244 shares in the last quarter. Hedge funds and other institutional investors own 94.71% of the company’s stock.

About iTeos Therapeutics (Get Rating)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

See Also

Insider Buying and Selling by Quarter for iTeos Therapeutics (NASDAQ:ITOS)

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.